Phase III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer

Trial summary:

The PATHOS trial aims to examine whether reducing the intensity of adjuvant treatment following transoral surgery (transoral laser microsurgery (TLM) or transoral robotic surgery (TORS)) in Human Papillomavirus (HPV) related Oropharyngeal Squamous Cell Cancer (OPSCC) patients will result in improved swallowing outcomes, whilst maintaining local control rates and survival. The trial aims to recruit 1100 patients from UK and international centres until the end 2024.

RT QA summary:

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.

QA Process	QA Activity	Required for Trial	Additional Details
Pre-Accrual	Facility Questionnaire
	Outlining Benchmark Case		2 cases
	Planning Benchmark Case		2 cases
	Dummy Run
During Accrual	Individual Case Review		Prospective review of first lateralised and non-lateralised patient
	Data collection		All patients
Dosimetry
QA Streamlining			CompARE, TORPEdO, BEST OF

RTTQA contact: pathos.enh-tr@nhs.net

Chief investigator: Prof Mererid Evans / Prof Terence Jones

RT Lead: Dr Nachi Palaniappan, Dr Matthew Beasley, Dr Richard Webster

Sponsor: Velindre University NHS Trust & Cardiff University,  PATHOS@cardiff.ac.uk

Funder: Cancer Research UK